Study of chronic thromboembolic pulmonary hypertension via analyzing the genome and transomics analyses.

A prospective observational study for clarifying the pathophysiology of chronic thromboembolic pulmonary hypertension via analyzing the genome and transomics analyses. - The genome and transomics analyses of chronic thromboembolic pulmonary hypertension.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000049092

Enrollment

150

Registered

2022-10-03

Start date

2022-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic thromboembolic pulmonary hypertension

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hospitalized patients of chronic thromboembolic pulmonary hypertension. hospitalized patients who have atrial fibrillation or deep vein thrombosis as a control group.

Exclusion criteria

Exclusion criteria: Patients with HBV, HCV or HIV virus, patients under using prednisolone, cancer patients under treatment or patients who have history of cancer, patients with psychosis having trouble to get consent form, or patients with dementia who need treatment.

Design outcomes

Primary

Measure	Time frame
The involvement of somatic gene mutation in the pathophysiology of chronic thromboembolic pulmonary hypertension.	—

Secondary

Measure	Time frame
Epigenome, transcriptome, and proteome data of the lesions. Plasma metabolome data.	—

Countries

Japan

Contacts

Public ContactTomoya Yamashita

Kobe University Hospital Division of Cardiovascular medicine

tomoya@med.kobe-u.ac.jp078-382-5846

Outcome results